KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $420.3 million.

  • Vertex Pharmaceuticals' Accounts Payables rose 619.0% to $420.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $420.3 million, marking a year-over-year increase of 619.0%. This contributed to the annual value of $413.0 million for FY2024, which is 1318.17% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Accounts Payables of $420.3 million as of Q3 2025, which was up 619.0% from $442.3 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Accounts Payables registered a high of $445.0 million during Q1 2025, and its lowest value of $126.9 million during Q3 2022.
  • Its 5-year average for Accounts Payables is $294.9 million, with a median of $327.9 million in 2024.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Accounts Payables surged by 19621.75% in 2023, and later plummeted by 966.94% in 2024.
  • Vertex Pharmaceuticals' Accounts Payables (Quarter) stood at $195.0 million in 2021, then surged by 55.85% to $303.9 million in 2022, then grew by 20.07% to $364.9 million in 2023, then increased by 13.18% to $413.0 million in 2024, then rose by 1.77% to $420.3 million in 2025.
  • Its last three reported values are $420.3 million in Q3 2025, $442.3 million for Q2 2025, and $445.0 million during Q1 2025.